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Abstract
The objective of the research was to study the features of impaired fibrinolytic and proteolytic activity of blood plasma in
patients with osteoarthritis (OA), depending on the age levels of comorbidity.
Material and methods. The age features of comorbid processes prevalence in 120 patients with OA were clinically studied,
fibrinolytic and proteolytic activity of blood, levels of fibrinogen and C-reactive protein were also studied using biochemical
methods.
Results. Comorbidity in patients with OA at the age under 50 was established low. The level of comorbidity increases to at
the age of 51-60, after 60 years the phenomenon of comorbidity is more significant by frequency and severity. The diseases
of the cardiovascular system dominated, including metabolic syndrome, diseases of the digestive tract and kidneys were less
frequent. Cardiovascular risk (CVR) levels were high after the age of 50, gastrointestinal risk was less frequent. Fibrinolysis
minor disorders were observed in patients with low comorbidity, namely fibrinolytic and proteolytic activity of blood as a part
of high CVR progressively deteriorated and the level of fibrinogen and C-reactive protein increased in the patients at the age
after 50 (especially 60) on the background of high comorbidity levels.
Conclusions. The level of comorbidity and CVR increased in patients with OA with age, increase in disease severity and
duration. These phenomena were accompanied by progressive disorders in fibrinolytic and proteolytic activity of the blood,
increased levels of fibrinogen and C-reactive protein as one of the components of CVR.
Keywords
osteoarthritis; comorbidity; fibrinolytic, proteolytic activity levels
Bukovinian State Medical University,Chernivtsi, Ukraine
Corresponding author: voloshka3@mail.ru
Problem statement and analysis of the
recent research
Osteoarthritis (OA) is one of the most common age-dependent
diseases which affect joints, with an inflammatory compo-
nent characterized by high level of poly- and comorbidity
[6, 9]. Among them the most common diseases include the
diseases of the cardiovascular system and digestive tract caus-
ing high levels of cardiovascular and gastrointestinal risks,
especially in connection with the use of antirheumatics [9,
11, 12]. Comorbidity and high cardiovascular risk (CVR) are
now recognized as the main issues in modern medicine [11,
13, 14]. The leading role of comorbidity requires more thor-
ough research and development of new strategic approaches
to diagnosis, treatment and prevention of internal diseases [6,
10]. Academician V.M. Kovalenko considers the definition of
pathogenic platforms for associated diseases to be relevant in
the problem of comorbidity in order to influence actively their
mechanisms and minimum use of drugs as a way to avoid
polypharmacy [6]. Most of scientific researches on CVR
predictors are based on the study of atherosclerotic vascular
endothelial dysfunction phenomena, etc. [11, 14]. However,
blood rheology including fibrinolytic and proteolytic activ-
ity of plasma plays an important role in the development of
CV-events [2]. The causes of these disorders may include
numerous comorbid processes inherent in patients with OA.
In particular, such disorders were detected in patients with
diabetes mellitus, hypothyroidism [1, 7], patients with COPD
and asthma [5], patients with OA and gastropathy [4]. How-
ever, the problem of comorbidity in patients with OA has been
insufficiently studied including changes in proteolytic and
fibrinolytic properties of blood depending on the stage of OA
and levels of comorbidity. The study of these interrelated pro-
cesses will help to understand better the pathogenic relation
and to improve treatment and prevention programs.
The objective of the researchwas to study the features of
in fibrinolytic and proteolytic activity of the blood in patients
with OA according to age levels of comorbidity.
1. Material and methods
Comprehensive examination of 120 patients with OA of I-III
clinical-radiological stages in the exacerbation at the age of
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37-76 years was conducted. Women dominated among the
patients (97 - 80.8%). The diagnosis of OA was made under
the Recommendations of EULAR (2010) and the order of
MOH of Ukraine of 12.10.2006 #676 “Clinical Protocol for
Provision of Medical Care to Patients with Osteoarthritis”.
Associated comorbidities were verified according to examina-
tions and the relevant protocols supported by the Ministry of
Health of Ukraine and by specialized professionals. Exclusion
criteria included patients with secondary OA, patients with pri-
mary OA, myocardial infarction or stroke, severe lesions and
functional disorders of internal organs, patients with cancer,
oncohematological processes, active ulcer of gastroduodenal
localization.
OA duration constituted 3-19 (12.1 ± 3.3) years, the du-
ration of comorbidities constituted 2-7 (3.1 ± 0.62) years.
All comorbid processes were in a state of unstable or stable
remission (diabetes mellitus type II - a state of compensation).
CVR level was determined by means of a calculator based
on SCORE scale [4]. The level of comorbidity was defined
by Charlson M.E et al. [15]. 30 apparently healthy individu-
als (AHI) of representative age (the control group) were also
examined.
The fibrinolytic activity of blood plasma was studied ac-
cording to azofibrin lysis (reagents from Danish Ltd, Lviv),
followed by the further determination of the total fibrinolytic
activity (TFA), non-enzymatic fibrinolytic activity (NFA) and
enzymatic fibrinolytic activity (EFA) by calculation method
(EFA = TFA-NFA). The research of blood proteolytic activity
was conducted with the help of azoalbumin lysis (breakdown
of low molecular weight proteins), azocasein (catalysis of high
molecular weight proteins) and azocol (decrease in collagen)
(reagents from Danish Ltd, Lviv) [2, 8].
Statistical data processing was conducted using the appli-
cation software package: Microsoft Excel, Statistica 6.0. The
arithmetic mean (M), mean error (m), the probability of dif-
ferences between comparative groups was determined using
Mann-Whitney test, Student’s t-test. Correlation analysis was
performed according to Pearson correlation coefficient. The
differences were considered statistically significant at p<0.05.
2. Results and Discussion
Determination of the prevalence and a range of comorbidities
in terms of age was the basis of the analysis. In this context,
OA patients were divided into three groups: under the age of
50, at the age of 51-60 and over 60 (Table 1).
According to Table 1, comorbidities were detected in
4.75% of the patients at the age of 50. Other patients had
2-3 comorbid processes at the early stages. Usually, one of
them was cardiovascular system (CVS) disease (hypertension
stage 1), other disease occurred before OA or NSAID-induced
gastropathy. OA was detected at I-II clinicoradiological stage.
All patients at the age of 51-60 had 4-6 comorbid diseases.
Moreover, they were clinically more significant. The patients
repeatedly consulted relevant specialists about their exacerba-
tions and took medicines prescribed by them. A wider range
of cardiovascular system diseases was observed as well as
frequent cases of diabetes mellitus type 2, obesity, cholecysto-
pancreato-hepatopathy and bowel diseases in the digestive
system. Genitourinary system disorders, OA mainly stage
II and less frequently of III radiologic stages became more
frequent.
OA manifested in polyosteoarthrosis of stage I and mainly
of stage II in patients older than 60. CVS comorbidities were
not only more significant, but they had symptoms of chronic
heart disease, metabolic syndrome and the range of digestive
system diseases became broader. In general, the patients were
diagnosed with 7-9 and more comorbidities. Combination
of hypertension and ischemic heart disease, and gastropathy,
cholecysto-pancreatopathy, steatohepatosis were more fre-
quent leading to high levels of CVR and gastrointestinal risks
(GIR), but CVR dominated. In this aspect, studying features
of fibrinolytic and proteolytic activity of blood seemed to be
important (Table 2).
No significant differences in proteolytic properties of
blood were detected in patients with OA at the age under
50 (with low comorbid processes) in comparison with healthy
individuals. However, the TFA was significantly reduced
(p<0.05) due to EFA. The changes constituted 9.3% and
28.8% respectively. Reliable increase in albumin lysis was
also noticed.
Reliable increase in the content of fibrinogen in the blood
(35.03%) was noticed in patients with OA at the age of 51-60
(high comorbidity) while decrease in total fibrinolytic activ-
ity (by 22.7%), non-enzymatic (by 21.2% ) and enzymatic
fibrinolytic activity (by 25.43%) was observed. At the same
time reliable increase in proteolysis of low-molecular (by
azoalbumin lysis) and high-molecular (by asacasein lysis)
weight proteins by 58.22% and 59.16% respectively, and also
collagen activity of blood (by azocol lysis) by 64.06% was
detected.
It was more significant in patients with OA with high co-
morbidity and at the age over 60 that in patients at the age of
51-60 years in terms of TFA and FFA, and lysis of low molec-
ular weight proteins was reliably worse than in patients under
the age of 60. It should be noted that patients with dominant
CVS and MS lesions suffered from more severe disorders of
fibrinolytic and proteolytic activity than in case of comorbid
gastroenterological processes prevalence or those of kidneys.
Moderate feedback between TFA and fibrinogen (r = - 0.47;
p<0.05) and direct correlation between the values of albumin
lysis and fibrinogen (r = 0.41; p<0.05), azocasein lysis of
and fibrinogen (r = 0.39; p<0.05), azocol and fibrinogen (r =
0.44; p<0.05) was detected in the patients at the age of 51-60.
These correlation principles increased but within moderate
intensity, TFA and fibrinogen r = -0.64 (p<0.01); values of
fibrinogen lysis and azoalbumin r = 0.58 (p<0.01); azocasein
and fibrinogen lysis r = 0.54 (p<0.01); azocol and fibrinogen
lysis r = 0.61 (p<0.01) in patients at the age over 60.
Therefore, patients with OA experienced decrease in the
fibrinolytic properties of blood and increase in the proteolytic
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Table 1. Age features of poly- and comorbid diseases in patients with osteoarthritis (n, %)
Nosology
Patients
under 50
(n=15)
Patients at the age of 51-60 (n=49) Patients over 60 (n=56) Total (n=120)
Without comorbidity 6 (5.0%) - - 6 (5.0%)
Arterial hypertension
stage 1
4 (26.67%)
14
(28.57%) 40.81%
12
(21.43%) 66.07%
30 (25.0%)
50.83%
Arterial hypertension
stage 2
- 6 (12.24%)
25
(44.64%)
31
(25.83%)
IHD, moderate forms 2 (13.33%) 7 (14.28%) 21 (37.5%) 30 (25.0%)
IHD, severe forms (with
heart failure, arrhyth-
mia)
- 1 (2.04%) 4 (7.14%) 5 (4.17%)
Obesity stage 1 3 (20%)
15
(30.61%) 44.89%
15
(26.78%) 76.78%
33 (27.5%)
56.67%
Obesity stage 2-3 - 7 (14.28%) 28 (50.0%)
35
(29.17%)
Diabetes mellitus type 2 - 5 (10.20%) 13 (23.21%) 18 (15.0%)
Steatohepatosis 2 (13.33%) 17 (34.69%) 37 (66.07%)
56
(46.67%) 53.34%
Steatohepatitis - 2 (4.08%) 6 (10.71%) 8 (6.67%)
Cerebral forms of
atherosclerosis with
dyscirculatory en-
cephalopathy stages
I-II
- 3 (6.12%) 11 (19.64%) 14 (11.67%)
Chronic cholecystitis 7 (46.67%) 24 (48.97%) 34 (60.71%) 65 (54.17%)
including calculous
cholecystitis
- 5 (10.20%) 7 (12.5%) 12 (10.0%)
Gastritis, duodenitis 8 (53.33%) 26 (53.06%) 32 (57.14%) 64 (53.33%)
Peptic ulcer - 3 (6.12%) 6 (10.71%) 9 (7.5%)
Chronic pancreatitis - 6 (12.24%) 15 (26.78%) 21 (17.5%)
Enterocolonopathy - 15 (30.61%) 29 (51.78%) 44 (36.67%)
COPD, bronchitis 1 (6.67%) 5 (10.20%) 7 (12.50%) 13 (10.83%)
Chronic renal disease
stages I-II
- 6 (12.24%) 6 (10.71%) 12 (10.0%)
Chronic adnexitis 1 (6.67%) 7 (14.28%) 6 (10.71%) 14 (11.74%)
Chronic prostatitis or
BPH
- 2 (4.08%) 3 (5.35%) 5 (4.17%)
ENT diseases 2 (13.33%) 4 (8.16%) 5 (8.93%) 11 (9.17%)
Eye diseases(cataract,
glaucoma)
1 (6.67%) 3 (6.12%) 5 (8.93%) 9 (7.5%)
Skin diseases (der-
matoses, mycoses)
1 (6.67%) 4 (8.16%) 6 (10.71%) 11 (9.17%)
processes along with the age growth of comorbidity. Os-
teoarthritis and almost all diagnosed comorbid processes are
known to be characterized by non-specific effects of oxidative
stress. Under these conditions partial breakdown of proteins
in the form of their fragmentation or even denaturation in the
tissues and blood occurs. These proteins are a substrate for
intracellular proteases [2]. Increase in the proteolysis enzyme
activity in the blood causes activation of the kinin-kallikrein,
the renin-angiotensin-aldosterone system and complement,
the development of inflammatory and destructive processes in
the body.
Fibrinolytic system plays an important role in maintain-
ing hemostasis providing normal blood flow in the vessels
[2]. The weakening process of fibrinolysis and increase in
fibrinogen level in the blood were found in the study group
of patients, indicating increased ability of blood to possi-
ble microthrombosis, impaired microcirculation and tissue
metabolism in all structures of the human body. The mech-
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Table 2. Indicators of fibrinolytic and proteolytic activity of plasma levels of fibrinogen and C-reactive protein in the blood of
patients with OA according to age comorbidity (M ± m, p)
Rates, units of measure-
ment
Apparently healthy
individuals, n=30
Patients with OA at
the age under 50 (low
comorbidity rate),
n=15
Patients with OA at
the age of 51-60
(high comorbidity
rate), n=49
Patients with OA at
the age over 60 (high
comorbidity rate),
n=56
Fibrinogen, g/l 3.54±0.32 3.78±0.36 4.78±0.33*** 5.1±0.42***
Blood TFA, E440/ml/h 1.63±0.05 1.48±0.07* 1.26±0.06*** 1.1±0.07***#
Blood NFA, E440/ml/h 1.04±0.04 1.06±0.05 0.82±0.06*** 0.73±0.04***
Blood EFA, E440/ml/h 0.59±0.03 0.42±0.04* 0.44±0.03* 0.38±0.02*#
Lysis of low molecular
weight proteins mmol/
azoalbumin/1 ml/h
2.92±0.12 3.06±0.17 4.62±0.16*** 4.96±0.18***#
Lysis of high molecu-
lar weight proteins mmol
/azocasein/1 ml/h
2.62±0.16 2.94±0.24 4.17±0.28*** 4.56±0.22***
Lysis of collagen
mmol/azocol/1ml/h
0.64±0.06 0.98±0.09* 1.05±0.07*** 1.39±0.11***
C-reactive protein, mg 2.8±0.18 5.2±0.46* 6.6±0.43*** 7.8±0.56*** #
Note.
* - the difference in the rates is reliable (p<0.05-0.001) compared to those in apparently healthy individuals;
** - the difference in the rates is reliable (p<0.5-0.01) compared to those in patients at the age under 50;
# - the difference in the rates is reliable (p<0.05) compared to those in patients at the age of 51-60.
anism of disorders in fibrinolytic and proteolytic activity of
blood in case of high level of comorbidity is probably very
complex, universal and non-specific, especially in case of the
cardiovascular system diseases prevalence. However, it is
important that they are integral components of high cardio-
vascular risk in these patients. In a complex regimen of their
treatment in the context of CVR prevention they should be
kept in mind as the metabolic basis of a number of disorders
and the means of metabolic and rheological correction should
be used.
3. Conclusions
1. The comorbidity occurs in patients with osteoarthri-
tis with age, increase in disease severity and duration
mainly due to the cardiovascular system disorders, meta-
bolic syndrome, digestive system diseases and increased
levels of cardiovascular and gastrointestinal risks.
2. Age-increasing levels of comorbidity in patients with
osteoarthritis are accompanied by significant progres-
sive decrease in fibrinolytic properties of blood, in-
creased levels of fibrinogen and increased blood prote-
olytic activity.
3. Disorders of proteolysis and fibrinolysis in the blood
of this group of patients are one of the pathophysi-
ological components of high cardiovascular risk and
vascular-metabolic disorders in different tissues and
organs. They should be taken into account in the imple-
mentation of preventive measures and as an addition to
the used rheological means of metabolic action.
4. Prospects for further research
Different medication with vascular-metabolic-rheological prop-
erties is advisable to be tested to determine criteria and dura-
tion of its use in the treatment of patients with OA and high
comorbidity.
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